urgent
need
molecular
marker
suitabl
allow
predict
therapi
outcom
individu
therapeut
protocol
ideal
marker
readili
detect
surrog
tissu
peripher
blood
lymphocyt
high
precis
appropri
technic
effort
function
character
cellular
protein
marker
often
complex
difficult
mani
studi
current
concentr
dna
genotyp
rna
express
analys
measur
steadyst
messeng
rna
mrna
level
circul
lymphocyt
good
choic
determin
effici
gene
transcript
also
correct
process
mainten
mrna
regul
mrna
express
howev
tissu
specif
affect
genet
endogen
factor
age
gender
potenti
bodi
mass
index
bmi
exogen
factor
like
exposur
tobacco
smoke
nutritiondepend
serum
antioxid
level
also
shown
influenc
mrna
express
obtain
reliabl
result
modifi
factor
taken
consider
togeth
high
technic
standard
isol
process
rna
throughout
experiment
protocol
contrast
genet
polymorph
inherit
genet
variat
present
cell
germin
somat
healthi
impair
individu
easili
determin
dna
avail
tissu
especi
polymorph
affect
gene
express
might
use
instead
costli
timeconsum
measur
mrna
level
howev
difficult
assess
impact
singlenucleotid
polymorph
highli
complex
cellular
process
mrna
express
use
molecular
biolog
method
cell
line
carri
certain
genotyp
associ
studi
evalu
correl
genet
variant
mrna
express
peripher
blood
lymphocyt
ampl
number
individu
provid
better
rational
use
genet
marker
analyz
correl
genotyp
mrna
level
three
dna
damag
respons
repair
gene
suggest
affect
therapi
outcom
select
gene
possibl
clinic
relev
also
preliminari
data
indic
express
level
gene
might
modul
specif
polymorph
see
thu
studi
lymphocyt
prostat
cancer
patient
reveal
whether
correl
two
paramet
may
support
use
clinic
set
nucleotid
excis
repair
gene
evid
variant
affect
platinum
treatmentinduc
toxic
two
polymorph
report
correl
therapi
outcom
mrna
level
c
also
report
locat
untransl
region
gene
suggest
influenc
mrna
stabil
c
polymorph
correl
better
surviv
lung
cancer
patient
follow
cisplatin
chemotherapi
addit
high
level
intratumor
mrna
associ
platinum
resist
variou
tumor
cell
line
experi
reveal
c
polymorph
associ
reduc
codon
usag
decreas
delay
induct
mrna
express
cisplatin
treatment
gene
encod
protein
interact
neg
regul
protein
polymorph
promot
region
g
also
report
found
associ
poor
prognosi
gastric
carcinoma
variant
enhanc
affin
transcript
factor
promot
region
extend
length
promoterbind
site
result
increas
mrna
express
level
shown
comparison
four
tumor
cell
line
carri
either
homozyg
wildtyp
variant
allel
polymorph
bp
repeat
intron
tumor
suppressor
gene
associ
risk
develop
acut
side
effect
radiotherapi
addit
polymorph
shown
associ
reduc
constitut
mrna
express
level
lymphoblastoid
cell
line
reduc
stabil
bp
insertioncarri
premrna
suggest
possibl
mechan
summari
publish
evid
function
impact
genet
variant
mainli
base
cell
cultur
experi
result
studi
small
sampl
size
regul
mrna
express
howev
complex
differ
cell
cultur
primari
cell
systemat
evalu
correl
primari
tissu
still
miss
investig
possibl
modifi
effect
select
polymorph
c
c
g
express
gene
measur
quantit
realtim
polymeras
chain
reaction
pcr
revers
transcript
rt
lymphocyt
cohort
prostat
cancer
patient
analyz
possibl
associ
genotyp
furthermor
haplotyp
well
potenti
modifi
factor
age
bmi
serum
antioxid
level
alcohol
tobacco
consumpt
includ
statist
evalu
cohort
unselect
prostat
cancer
patient
recruit
depart
radiolog
univers
hospit
heidelberg
prospect
epidemiolog
studi
patient
receiv
radiotherapi
includ
studi
approv
ethic
committe
medic
faculti
univers
heidelberg
ref
patient
gave
inform
written
consent
take
part
studi
data
histopatholog
tumor
therapi
radiationrel
side
effect
collect
patient
hospit
record
demograph
epidemiolog
inform
gather
use
selfadminist
patient
questionnair
detail
epidemiolog
descript
studi
design
particip
publish
elsewher
selfadminist
questionnair
includ
detail
inform
lifetim
smoke
habit
alcohol
consumpt
particip
ask
began
smoke
type
product
consum
amount
smoke
date
cessat
chang
smoke
habit
exsmok
person
report
smoke
regularli
past
current
smoker
report
regular
smoke
time
complet
questionnair
addit
packyear
comput
averag
number
pack
per
day
time
total
number
year
smoke
assum
cigarett
per
pack
patient
stratifi
three
group
accord
variabl
packyear
packyear
packyear
packyear
base
daili
alcohol
consumpt
patient
divid
three
group
gday
import
characterist
studi
cohort
shown
tabl
mean
age
year
mean
bmi
equal
kgm
patient
never
smoker
exsmok
current
smoker
venou
blood
sampl
ml
obtain
ethylenediaminetetraacet
acidlay
monovett
patient
prior
radiotherapi
within
h
blood
sampl
peripher
lood
lymphocyt
isol
gradient
centrifug
overlay
whole
blood
axisshield
oslo
norway
tube
greiner
bioon
gmbh
frickenhausen
germani
centrifug
g
min
room
temperatur
lymphocyt
purifi
two
wash
step
phosphatebuff
salin
rna
isol
perform
directli
afterward
rna
isol
ident
ml
buffi
coat
healthi
male
subject
receiv
heidelberg
blood
bank
serv
calibr
rna
quantif
roch
appli
scienc
mannheim
germani
technic
note
use
experi
total
rna
isol
modifi
singlestep
method
use
invitrogen
karlsruh
germani
accord
manufactur
protocol
cell
lyse
addit
ml
trizol
per
cell
repetit
pipet
aqueou
organ
phase
separ
addit
chloroform
subsequ
centrifug
transfer
aqueou
phase
rna
recov
precipit
isopropanol
centrifug
wash
ethanol
pellet
dri
dissolv
rnasefre
h
rna
integr
concentr
determin
use
agil
bioanalyz
rna
nano
kit
agil
technolog
santa
clara
ca
usa
two
microgram
total
rna
revers
transcrib
use
superscript
ii
system
invitrogen
mm
deoxynucleotid
triphosph
mbi
fermenta
st
leonroth
germani
u
rnasin
promega
mannheim
germani
oligodt
primer
appli
biosystem
cheshir
uk
reaction
incub
min
follow
incub
min
express
level
target
refer
gene
analyz
lightcycl
roch
diagnost
mannheim
germani
typic
amplif
mixtur
contain
complementari
dna
cdna
sampl
mm
mgcl
primer
lightcycl
faststart
master
sybr
green
mix
contain
buffer
taq
dna
polymeras
roch
diagnost
calibr
sampl
measur
standard
cdna
realtim
pcr
experi
adjust
possibl
runtorun
variat
evalu
experi
socal
calibr
normal
rel
quantif
method
effici
correct
use
roch
appli
scienc
technic
note
oligonucleotid
design
use
primer
softwar
whitehead
institut
biomed
research
cambridg
usa
amplicon
one
primer
cover
border
avoid
possibl
amplif
residu
contamin
genom
dna
see
tabl
ii
tbp
use
refer
gene
express
level
lymphocyt
expect
similar
gene
analyz
pcr
effici
measur
use
triplic
cdna
dilut
seri
pcr
condit
optim
gene
order
obtain
pcr
effici
close
theoret
optim
valu
thermal
cycl
condit
cycl
min
cycl
denatur
hybrid
tbp
elong
cross
point
repres
pcr
cycl
pcr
product
detect
determin
sampl
use
second
deriv
maximum
method
lightcycl
softwar
roch
diagnost
qualiti
control
ensur
nontempl
control
determin
melt
point
pcr
product
sampl
exact
concord
melt
point
sequenceproof
amplicon
includ
lightcycl
run
calibr
sampl
measur
triplic
patient
sampl
determin
duplic
mean
cross
point
valu
use
calcul
variabl
realtim
pcr
determin
variat
rt
pcr
togeth
rt
reaction
spike
ng
mrna
arabidopsi
thaliana
stratagen
la
jolla
ca
usa
recoveri
spike
quantit
realtim
pcr
serv
control
measur
effici
rt
step
coeffici
variat
result
rt
quantif
determin
genom
dna
isol
whole
blood
sampl
use
qiagen
qiaamp
dna
blood
midi
kit
qiagen
hilden
germani
primer
probe
given
tabl
ii
polymorph
c
chromosom
locu
c
chromosom
locu
determin
rapid
capillari
pcr
use
sequencespecif
probe
melt
curv
analysi
lightcycl
softwar
version
roch
diagnost
probe
design
prepar
tib
molbiol
berlin
germani
analysi
perform
volum
glass
capillari
roch
diagnost
use
qiagen
reagent
pcr
buffer
mm
mgcl
mm
deoxynucleotid
triphosph
bovin
serum
albumin
glycerol
u
taq
dna
polymeras
primer
probe
c
probe
c
ng
dna
reaction
condit
follow
initi
denatur
min
follow
cycl
denatur
anneal
elong
melt
curv
analysi
perform
initi
denatur
step
follow
slow
heat
ramp
rate
continu
fluoresc
detect
ten
percent
sampl
randomli
select
repeat
method
addit
sampl
analyz
restrict
fragment
length
polymorph
genotyp
result
show
concord
chromosom
locu
polymorph
bp
insert
determin
use
method
tan
et
al
g
polymorph
chromosom
locu
promot
region
determin
use
restrict
fragment
length
polymorph
method
modifi
accord
sotamaa
et
al
analysi
perform
volum
use
qiagen
reagent
pcr
buffer
mm
mgcl
mm
deoxynucleotid
triphosph
u
taq
dna
polymeras
primer
ng
dna
reaction
condit
follow
initi
denatur
min
cycl
denatur
anneal
elong
final
extens
min
bp
pcr
product
digest
h
volum
new
england
biolab
frankfurt
germani
visual
agaros
gel
show
three
fragment
bp
homozyg
gallel
carrier
two
fragment
bp
homozyg
tallel
carrier
pcr
product
addit
restrict
site
result
bp
fragment
control
complet
digest
ten
percent
sampl
randomli
select
repeat
nontempl
control
nclude
amplif
set
genotyp
polymorph
evalu
two
independ
observ
genotyp
result
polymorph
show
concord
plasma
patient
separ
whole
blood
lymphocyt
isol
store
nine
differ
antioxid
measur
sampl
correspond
studi
popul
tabl
highperform
liquid
chromatographi
analys
tocopherol
carotenoid
canthaxanthin
cryptoxanthin
lycopen
lutein
done
describ
hess
et
al
carotenoid
estim
stabl
least
year
temperatur
ascorb
acid
concentr
determin
photometr
wavelength
nm
concern
plasma
carotenoid
vitamin
e
recoveri
standard
substanc
ad
plasma
sampl
laid
coeffici
variat
calcul
repeat
n
measur
sampl
mean
recoveri
ascorb
acid
ad
plasma
sampl
coeffici
variat
n
nonparametr
test
use
determin
differ
three
categor
valu
continu
variabl
nonparametr
wilcoxon
test
comparison
two
categori
spearman
rank
correl
test
use
analyz
correl
polymorph
test
deviat
equilibrium
compar
observ
expect
genotyp
frequenc
use
chisquar
test
linkag
disequilibrium
two
differ
marker
c
c
estim
use
estim
haplotyp
program
haplo
diplotyp
reconstruct
use
phase
program
version
odd
ratio
confid
interv
comput
use
multivari
uncondit
logist
regress
analysi
estim
produc
phreg
procedur
statist
softwar
packag
sa
releas
sa
institut
cari
nc
mrna
level
determin
lymphocyt
sampl
taken
prostat
cancer
patient
prior
radiotherapi
complet
data
three
gene
obtain
patient
sampl
miss
due
insuffici
rna
qualiti
insuffici
pcr
product
qualiti
median
mrna
express
valu
rang
summar
tabl
iii
consider
interindividu
differ
mrna
level
observ
among
studi
subject
highest
variat
follow
variat
coeffici
variat
calcul
express
valu
result
variabl
clearli
exceed
valu
observ
experiment
variat
signific
correl
mrna
express
level
observ
among
gene
strongest
correl
coeffici
r
p
weakest
r
p
effect
differ
anthropometr
lifestyl
factor
mrna
express
studi
spearman
correl
analys
age
bmi
alcohol
consumpt
smoke
habit
constitut
mrna
express
show
statist
signific
associ
p
similarli
plasma
concentr
ascorb
acid
tocopherol
carotenoid
canthaxanthin
cryptoxanthin
lycopen
lutein
significantli
correl
mrna
express
level
mrna
express
display
posit
correl
level
r
p
neg
correl
canthaxanthin
r
p
lutein
r
p
respect
genotyp
distribut
four
polymorph
c
c
g
determin
patient
tabl
iv
allel
frequenc
gener
consist
publish
report
c
c
g
genotyp
distribut
equilibrium
high
correl
found
c
c
polymorph
indic
linkag
disequilibrium
p
reconstruct
diplotyp
associ
express
analyz
eight
differ
diplotyp
observ
studi
popul
tabl
v
polymorph
c
c
lower
mrna
level
associ
increas
number
respect
c
allel
associ
howev
statist
signific
tabl
iv
furthermor
correl
mrna
level
genotyp
mrna
express
stratifi
accord
diplotyp
group
shown
tabl
v
diplotyp
group
repres
total
studi
popul
exclud
statist
analysi
signific
differ
mrna
express
found
among
remain
five
diplotyp
group
p
cc
haplotyp
carrier
cc
carrier
show
decreas
mrna
express
relat
group
analyz
compar
noncc
carrier
median
mrna
express
valu
cc
carrier
remark
lower
noncarri
use
wilcoxon
test
differ
mrna
express
found
highli
signific
p
low
mrna
express
might
associ
reduc
cellular
dna
repair
activ
could
lead
increas
genom
instabl
better
therapi
respons
therefor
appli
logist
regress
model
assess
effect
diplotyp
haplotyp
risk
low
mrna
express
tabl
v
risk
estim
model
adjust
factor
potenti
modifi
mrna
level
antioxid
plasma
level
age
alcohol
tobacco
consumpt
carrier
frequent
diplotyp
ct
ct
use
refer
increas
odd
ratio
confid
interv
observ
reduc
mrna
express
cc
ct
diplotyp
carrier
compar
noncarri
cc
carrier
adjust
odd
ratio
confid
interv
low
mrna
express
aim
studi
analyz
whether
genet
variat
dna
damag
respons
repair
gene
contribut
mrna
express
measur
peripher
blood
lymphocyt
earlier
report
suggest
c
c
g
polymorph
affect
mrna
level
variou
cell
line
studi
primari
lymphocyt
individu
observ
effect
polymorph
analyz
separ
weak
reach
statist
signific
trend
similar
publish
effect
howev
observ
polymorph
bond
et
al
observ
elev
mrna
express
cell
line
homozyg
gg
carrier
g
also
found
higher
median
mrna
level
homozyg
gg
individu
compar
tallel
carrier
decreas
mrna
express
describ
cell
carri
compar
carri
cell
observ
similar
differ
mrna
express
primari
lymphocyt
carri
genotyp
effect
c
genotyp
mrna
express
report
small
studi
investig
korean
head
neck
cancer
patient
observ
confirm
result
tt
carrier
c
polymorph
show
higher
mrna
express
level
studi
contrast
result
observ
two
cell
line
carri
genet
variant
elev
express
tallel
carrier
also
observ
colorect
tumor
tissu
contrast
analys
singl
polymorph
found
distinct
genotyp
combin
cc
significantli
associ
decreas
mrna
valu
reconstruct
haplotyp
subsequ
statist
evalu
reveal
distinctli
lower
mrna
level
cc
carrier
noncarri
p
alreadi
one
cc
allel
reduc
mrna
express
could
argu
cc
haplotyp
exert
dominantneg
effect
regul
mrna
express
would
impli
genet
polymorph
natur
modul
mrna
level
prostat
cancer
patient
thu
affect
therapi
outcom
inde
differ
mrna
level
observ
two
studi
popul
express
use
predict
marker
therapi
outcom
singlenucleotid
polymorph
known
analyz
studi
therefor
rule
polymorph
show
stronger
correl
mrna
express
gene
restrict
analysi
select
genet
variant
measur
associ
alreadi
report
therebi
also
limit
number
statist
test
risk
falseposit
find
avoid
import
experiment
error
sourc
determin
rna
express
use
rel
quantif
realtim
pcr
rt
procedur
regard
reliabl
method
rna
quantif
present
experiment
step
optim
control
care
rna
cdna
integr
appli
tbp
refer
gene
normal
measur
calibr
adjust
experiment
differ
pcr
measur
increas
probabl
observ
interindividu
differ
mrna
express
true
differ
affect
high
experiment
variabl
howev
exclud
minor
part
differ
introduc
normal
step
use
tbp
refer
tbp
select
wide
accept
reliabl
refer
gene
ii
show
express
level
compar
target
gene
valid
express
data
also
support
compar
express
valu
publish
similar
studi
mrna
express
determin
lymphocyt
bladder
cancer
patient
observ
interindividu
variat
express
slightli
higher
prostat
cancer
patient
report
lung
head
neck
cancer
patient
analyz
use
convent
multiplex
knowledg
first
studi
report
interindividu
variat
express
signific
correl
mrna
express
level
observ
stronger
correl
express
might
explain
tight
function
interact
protein
regul
dna
damag
respons
measur
mrna
express
valu
could
affect
number
endogen
exogen
factor
age
tobacco
consumpt
antioxid
level
plasma
decreas
mrna
express
increas
age
recent
report
detect
studi
probabl
absenc
younger
patient
within
studi
cohort
older
year
tobacco
consumpt
also
signific
effect
mrna
express
studi
contrast
associ
found
level
smoke
head
neck
cancer
patient
may
due
low
percentag
current
smoker
cohort
antioxid
eg
nutrit
sourc
import
cellular
protect
agent
oxid
damag
act
concert
cellular
defens
mechan
dna
repair
conceiv
antioxid
modul
intracellular
level
reactiv
oxid
speci
might
also
influenc
express
investig
gene
analys
show
correl
antioxid
level
blood
plasma
mrna
express
contrast
express
posit
associ
plasma
level
neg
correl
canthaxanthin
lutein
controversi
report
effect
carotenoid
mrna
express
dna
repair
gene
intervent
studi
fruit
veget
antioxid
show
effect
compon
express
healthi
subject
astley
et
al
report
howev
enhanc
dna
repair
activ
healthi
subject
receiv
carotenoidenrich
diet
result
show
discern
effect
antioxid
mrna
express
prostat
cancer
patient
patient
might
inflict
stronger
oxid
stress
due
diseas
make
effect
antioxid
pronounc
patient
compar
healthi
subject
consequ
observ
modifi
effect
antioxid
express
consid
mrna
express
explor
biomark
therapi
outcom
found
low
mrna
express
cc
carrier
account
modifi
factor
antioxid
low
mrna
express
might
use
risk
marker
also
found
relat
reduc
dna
repair
capac
furthermor
low
express
patient
ovarian
tumor
report
associ
increas
clinic
chemotherapi
sensit
express
peripher
blood
lymphocyt
recent
found
reflect
express
gene
head
neck
cancer
tissu
suggest
indic
therapi
success
ratio
mrna
express
tumor
head
neck
versu
normal
tissu
report
predict
respons
neoadjuv
therapi
cisplatin
radiat
summari
result
demonstr
consider
interindividu
differ
mrna
express
among
prostat
cancer
patient
differ
least
partial
attribut
genet
variat
also
modifi
extrins
intrins
factor
antioxid
weak
effect
singl
polymorph
express
detect
carrier
cc
haplotyp
significantli
lower
express
valu
noncarri
low
express
might
associ
reduc
dna
repair
better
chemotherapi
radiotherapi
respons
studi
use
primari
lymphocyt
suitabl
surrog
cell
assess
impact
molecular
marker
clinicalepidemiolog
set
target
tissu
sampl
difficult
obtain
avail
use
invas
procedur
publish
studi
aim
character
function
impact
polymorph
mainli
perform
immort
tumor
cell
line
howev
cell
might
cellular
characterist
consider
differ
primari
lymphocyt
thu
explain
observ
inconsist
therefor
ex
vivo
result
patient
contribut
better
understand
impact
genet
variant
mrna
express
dna
repair
gene
valid
analys
marker
provid
valuabl
tool
assess
therapi
respons
german
bundesamt
strahlenschutz
salzgitt
stsch
stsch
